抗抑郁药治疗共病抑郁与躯体疾病患者的疗效与安全性:伞形系统综述与荟萃分析
该伞形系统综述纳入52项荟萃分析、覆盖27种躯体疾病,发现抗抑郁药较安慰剂可改善共病抑郁(SMD 0.42,95%CI 0.30-0.54),但全因停药(RR 1.17)和因不良反应停药(RR 1.39)风险更高,同时应答率(RR 1.54)和缓解率(RR 1.43)更高,并更可能预防抑郁发生(RR 0.43)。
要点
- 抗抑郁药对共病躯体疾病的抑郁有效,合并SMD为0.42(95%CI 0.30-0.54)。
- 心肌梗死、功能性胸痛和冠心病效应量较大,腰痛和创伤性脑损伤效应量较小。
- 抗抑郁药可接受性和耐受性劣于安慰剂,但应答和缓解率更高,并能预防抑郁发生。
核心结论
- 抗抑郁药在治疗和预防共病躯体疾病患者的抑郁方面有效且安全,但多数躯体疾病缺乏大型高质量随机对照试验。
研究设计与样本
- 伞形系统综述与荟萃分析,检索PubMed和EMBASE从建库至2023年3月31日,纳入52项荟萃分析、覆盖27种躯体疾病。
- 采用AMSTAR-2和AMSTAR-Content评估质量,平均AMSTAR-2评分为9.3(SD 3.1,满分16),平均AMSTAR-Content评分为2.4(SD 1.9,满分9)。
主要发现
- 23项荟萃分析显示抗抑郁药较安慰剂改善抑郁,SMD为0.42(95%CI 0.30-0.54),I²=76.5%。
- 心肌梗死SMD为1.38(95%CI 0.82-1.93),功能性胸痛SMD为0.87(95%CI 0.08-1.67),冠心病SMD为0.83(95%CI 0.32-1.33)。
- 腰痛SMD为0.06(95%CI 0.17-0.39),创伤性脑损伤SMD为0.08(95%CI -0.28至0.45)。
- 24项荟萃分析显示抗抑郁药全因停药风险更高,RR为1.17(95%CI 1.02-1.32);18项荟萃分析显示因不良反应停药风险更高,RR为1.39(95%CI 1.13-1.64)。
- 8项荟萃分析显示应答率更高,RR为1.54(95%CI 1.14-1.94);6项荟萃分析显示缓解率更高,RR为1.43(95%CI 1.25-1.61);7项荟萃分析显示预防抑郁更有效,RR为0.43(95%CI 0.33-0.53)。
关键数值与推荐
- 纳入标准为安慰剂或活性对照随机对照试验的荟萃分析,研究抗抑郁药治疗躯体疾病患者的抑郁。
- 当同一躯体疾病有多项荟萃分析时,纳入最大的一项。
临床怎么用
- 对共病躯体疾病的抑郁患者,抗抑郁药可改善抑郁症状且应答和缓解率更高,但需监测可接受性和耐受性。
- 抗抑郁药可用于预防共病躯体疾病患者的抑郁发生。
局限性
- 多数躯体疾病缺乏大型高质量随机对照试验。
- 纳入荟萃分析的平均AMSTAR-2质量评分为9.3(SD 3.1,满分16),平均AMSTAR-Content评分为2.4(SD 1.9,满分9)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Every third to sixth patient with medical diseases receives antidepressants, but regulatory trials typically exclude comorbid medical diseases. Meta-analyses of antidepressants have shown small to medium effect sizes, but generalizability to clinical settings is unclear, where medical comorbidity is highly prevalent. OBJECTIVE: To perform an umbrella systematic review of the meta-analytic evidence and meta-analysis of the efficacy and safety of antidepressant use in populations with medical diseases and comorbid depression. DATA SOURCES: PubMed and EMBASE were searched from inception until March 31, 2023, for systematic reviews with or without meta-analyses of randomized clinical trials (RCTs) examining the efficacy and safety of antidepressants for treatment or prevention of comorbid depression in any medical disease. STUDY SELECTION: Meta-analyses of placebo- or active-controlled RCTs studying antidepressants for depression in individuals with medical diseases. DATA EXTRACTION AND SYNTHESIS: Data extraction and quality assessment using A Measurement Tool for the Assessment of Multiple Systematic Reviews (AMSTAR-2 and AMSTAR-Content) were performed by pairs of independent reviewers following PRISMA guidelines. When several meta-analyses studied the same medical disease, the largest meta-analysis was included. Random-effects meta-analyses pooled data on the primary outcome (efficacy), key secondary outcomes (acceptability and tolerability), and additional secondary outcomes (response and remission). MAIN OUTCOMES AND MEASURES: Antidepressant efficacy presented as standardized mean differences (SMDs) and tolerability (discontinuation for adverse effects) and acceptability (all-cause discontinuation) presented as risk ratios (RRs). RESULTS: Of 6587 references, 176 systematic reviews were identified in 43 medical diseases. Altogether, 52 meta-analyses in 27 medical diseases were included in the evidence synthesis (mean [SD] AMSTAR-2 quality score, 9.3 [3.1], with a maximum possible of 16; mean [SD] AMSTAR-Content score, 2.4 [1.9], with a maximum possible of 9). Across medical diseases (23 meta-analyses), antidepressants improved depression vs placebo (SMD, 0.42 [95% CI, 0.30-0.54]; I2 = 76.5%), with the largest SMDs for myocardial infarction (SMD, 1.38 [95% CI, 0.82-1.93]), functional chest pain (SMD, 0.87 [95% CI, 0.08-1.67]), and coronary artery disease (SMD, 0.83 [95% CI, 0.32-1.33]) and the smallest for low back pain (SMD, 0.06 [95% CI, 0.17-0.39]) and traumatic brain injury (SMD, 0.08 [95% CI, -0.28 to 0.45]). Antidepressants showed worse acceptability (24 meta-analyses; RR, 1.17 [95% CI, 1.02-1.32]) and tolerability (18 meta-analyses; RR, 1.39 [95% CI, 1.13-1.64]) compared with placebo. Antidepressants led to higher rates of response (8 meta-analyses; RR, 1.54 [95% CI, 1.14-1.94]) and remission (6 meta-analyses; RR, 1.43 [95% CI, 1.25-1.61]) than placebo. Antidepressants more likely prevented depression than placebo (7 meta-analyses; RR, 0.43 [95% CI, 0.33-0.53]). CONCLUSIONS AND RELEVANCE: The results of this umbrella systematic review of meta-analyses found that antidepressants are effective and safe in treating and preventing depression in patients with comorbid medical disease. However, few large, high-quality RCTs exist in most medical diseases.
引用
- Köhler-Forsberg O, Stiglbauer V, Brasanac J, et al. Efficacy and Safety of Antidepressants in Patients With Comorbid Depression and Medical Diseases: An Umbrella Systematic Review and Meta-Analysis. JAMA Psychiatry. 2023. PMID: 37672261. doi:10.1001/jamapsychiatry.2023.2983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。